Medtronic (MDT)
(Delayed Data from NYSE)
$79.97 USD
+0.57 (0.72%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $79.95 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.97 USD
+0.57 (0.72%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $79.95 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Medtronic (MDT) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Medtronic (MDT) closed at $79.30 in the latest trading session, marking a -0.23% move from the prior day.
Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $78.10, moving +1.32% from the previous trading session.
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $77.06, representing a +0.23% change from its previous close.
Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG).
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
by Urmimala Biswas
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Medtronic (MDT) Shares Positive Data for MiniMed 780G System
by Zacks Equity Research
Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.
3 Generative AI-Based MedTech Stocks to Keep an Eye On
by Moumi Mondal
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes
by Zacks Equity Research
For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.
Top Stock Reports for NVIDIA, Tesla & Linde
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Tesla, Inc. (TSLA) and Linde plc (LIN), as well as two micro-cap stocks Servotronics, Inc. (SVT) and The Cato Corporation (CATO).
Watch These 5 Stocks That Recently Hiked Dividends
by Santanu Roy
Investors may keep a tab on stocks like HLNE, RL, SPTN, EQH and MDT, which have lately hiked their dividend payments.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
by Zacks Equity Research
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medtronic (MDT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.69% and 1.80%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade
by Zacks Equity Research
Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
Unlocking Q4 Potential of Medtronic (MDT): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know
by Zacks Equity Research
Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $83.52, denoting a +0.82% change from the preceding trading day.
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
by Moumi Mondal
Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -22.22% and 6.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?